Dr. Howard Verrico reports

SIRONA BIOCHEM HIRES CONTRACT RESEARCH ORGANIZATION FOR MANUFACTURING PROCESS OPTIMIZATION FOR TFC-1067

Sirona Biochem Corp. has commissioned contract research organization (CRO) Roowin to develop the final chemical process required for large-scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona's novel skin lightening agent.

Sirona anticipates the need for multiple-kilogram production of TFC-1067 in the short term and is therefore taking this necessary intermediate step. Sirona will then proceed to manufacture an inventory of TFC-1067 of up to 20 kilograms to be ready for anticipated orders. Due to the high potency of the compound, each kilogram will supply Sirona's active skin lightening ingredient to produce 10,000 consumer-size (50 millilitres) containers of finished product.

"The chemistry of TFChem (Sirona's subsidiary) is unique and our science team has an excellent understanding of this chemistry. We have already successfully worked on production of TFC-1067 at the kilogram scale," reported Patrice Rool, chief executive officer of Roowin. "Our scientists will collaborate with TFChem to develop the most efficient final process to manufacture TFC-1067. We are very excited to be a part of the ongoing development of this innovative skin lightener."

"Roowin's expertise in manufacturing process development will move TFC-1067 closer to final commercialization. In addition, our scientists at TFChem have developed new chemistry that will further improve manufacturing efficiencies and lower cost of goods," Dr. Howard Verrico concluded. "The new manufacturing process for TFC-1067 we anticipate will be used at manufacturing sites globally down the road. Roowin has extensive experience with our chemistry and we are excited to be working together again."

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules, with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

We seek Safe Harbor.